Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PVS1_StrongPP4_ModeratePM2_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_000249.4: c.1667G>A variant in MLH1 is a missense variant predicted to cause substitution of Serin by Asparagin at amino acid 556 (p.Ser556Asn).PVS1_STR is met since c.1667G>A is a G>non-G at last base of exon if first 6 bases of the intron are not GTRRGT. The variant is not reported in gnomAD v4.1 (PM2_supporting). The variant was detected in 2 independent CRC/Endometrial MSI-H tumours using a standard panel of 5-10 markers and/or loss of MMR protein expression consistent with the variant location (PP4). In summary, this variant meets the criteria to be classified as likely pathogenic for Lynch-Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen InSiGHT Hereditary Colorectal Cancer/ Polyposis VCEP: PVS1_STR, PM2_SUP, PP4 (VCEP specifications version 1) LINK:https://erepo.genome.network/evrepo/ui/classification/CA352060789/MONDO:0007356/115
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
Likely pathogenic, criteria provided, single submitter
clinical testing
GeneDx
Sep 10, 2019
Not observed in large population cohorts (Lek 2016); Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Whitworth 2015, Sjursen 2016, Yurgelun 2017); This variant is associated with the following publications: (PMID: 25248401, 27064304, 22949387, 28135145, 30521064, 30720243) -
Likely pathogenic, criteria provided, single submitter
clinical testing
CeGaT Center for Human Genetics Tuebingen
Apr 01, 2023
MLH1: PM1, PM2, PS4:Moderate, PP1 -
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter
clinical testing
Baylor Genetics
Apr 20, 2022
- -
Lynch-like syndrome Pathogenic:1
Likely pathogenic, no assertion criteria provided
clinical testing
Constitutional Genetics Lab, Leon Berard Cancer Center
This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 556 of the MLH1 protein (p.Ser556Asn). This variant also falls at the last nucleotide of exon 14, which is part of the consensus splice site for this exon. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This missense change has been observed in individuals with colorectal cancer and clinical features of Lynch syndrome (PMID: 27064304, 28135145; Invitae; externalcommunication). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 449776). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
The c.1667G>A pathogenic mutation (also known as p.S556N), located in coding exon 14 of the MLH1 gene, results from a G to A substitution at nucleotide position 1667. The amino acid change results in serine to asparagine at codon 556, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 14, which makes it likely to have some effect on normal mRNA splicing. This alteration has been identified in multiple families fulfilling Amsterdam criteria (Sjursen W et al. Mol Genet Genomic Med. 2016 Mar;4:223-31; Yurgelun MBJ. Clin. Oncol. 2017 Apr;35(10):1086-1095; Jiang W et al. Int J Cancer, 2019 05;144:2161-2168). Another alteration at this same nucleotide position, c.1667G>T, has been shown to result in the use of a cryptic splice site that leads to a frameshift predicted to create a truncated protein (Sharp et al. Hum Mutat. 2004 Sep;24(3):272; Desmet et al. Nucleic Acids Res. 2009 May;37(9):e67). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Lynch syndrome 1 Uncertain:1
Uncertain significance, no assertion criteria provided